CHICAGO — Combining golimumab and guselkumab into JNJ-78934804, a fixed-dose co-antibody therapy, helped overcome treatment failure in inflammatory bowel disease and exceeded dose-dependent benefits of either drug alone, according to data.
Two parallel phase 2b trials combining the anti-tumor necrosis factor and anti-interleukin-23 medications in Crohn’s disease and ulcerative colitis, DUET-CD and DUET-UC, were presented by lead authors at Digestive Disease Week.
“Results show that people with Crohn’s disease who have had inadequate response to two or more systemic therapies do strikingly

In this Healio video exclusive, Leonard H. Calabrese, DO, chief medical editor of Healio Rheumatology, discusses the latest cover story on how lower pay and longer training requirements have stymied the pediatric rheumatology workforce.
“The real issue that I see is the problem with pediatric rheumatology,” he said. “This is an underserved area, it is undermanned, and there are some really interesting advances, I think, in being creative about training generated by the task force at the ACR that we will be discussing in our cover story.”
Calabrese additionally